IL218968A0 - Polypeptides for binding the " receptor for advanced glycation endproducts" as well as compositions and methods involving the same - Google Patents

Polypeptides for binding the " receptor for advanced glycation endproducts" as well as compositions and methods involving the same

Info

Publication number
IL218968A0
IL218968A0 IL218968A IL21896812A IL218968A0 IL 218968 A0 IL218968 A0 IL 218968A0 IL 218968 A IL218968 A IL 218968A IL 21896812 A IL21896812 A IL 21896812A IL 218968 A0 IL218968 A0 IL 218968A0
Authority
IL
Israel
Prior art keywords
polypeptides
receptor
binding
compositions
well
Prior art date
Application number
IL218968A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09290778A external-priority patent/EP2308896A1/fr
Priority claimed from EP09290845A external-priority patent/EP2319871A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL218968A0 publication Critical patent/IL218968A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
IL218968A 2009-10-09 2012-04-01 Polypeptides for binding the " receptor for advanced glycation endproducts" as well as compositions and methods involving the same IL218968A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290778A EP2308896A1 (fr) 2009-10-09 2009-10-09 Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant
EP09290845A EP2319871A1 (fr) 2009-11-05 2009-11-05 Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant
PCT/EP2010/065124 WO2011042548A1 (fr) 2009-10-09 2010-10-08 Polypeptides de liaison au « récepteur de produits terminaux de glycation avancée » ainsi que compositions et procédés les mettant en jeu

Publications (1)

Publication Number Publication Date
IL218968A0 true IL218968A0 (en) 2012-07-31

Family

ID=43448431

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218968A IL218968A0 (en) 2009-10-09 2012-04-01 Polypeptides for binding the " receptor for advanced glycation endproducts" as well as compositions and methods involving the same

Country Status (20)

Country Link
US (1) US20120282637A1 (fr)
EP (1) EP2486058A1 (fr)
JP (1) JP2013507115A (fr)
KR (1) KR20120089863A (fr)
CN (1) CN102686611A (fr)
AU (1) AU2010305374A1 (fr)
BR (1) BR112012007821A2 (fr)
CA (1) CA2777237A1 (fr)
CL (1) CL2012000886A1 (fr)
CR (1) CR20120139A (fr)
EC (1) ECSP12011787A (fr)
IL (1) IL218968A0 (fr)
MA (1) MA33661B1 (fr)
MX (1) MX2012004090A (fr)
PE (1) PE20121689A1 (fr)
PH (1) PH12012500564A1 (fr)
RU (1) RU2558301C2 (fr)
TN (1) TN2012000138A1 (fr)
WO (1) WO2011042548A1 (fr)
ZA (1) ZA201202099B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2014167826A1 (fr) * 2013-04-08 2014-10-16 株式会社免疫生物研究所 ANTICORPS RECONNAISSANT SPÉCIFIQUEMENT LA SURFACE DE CLIVAGE DU FRAGMENT C-TERMINAL APRÈS CLIVAGE DU PRÉCURSEUR DE LA PROTÉINE AMYLOÏDE PAR L'α-SÉCRÉTASE ET SON UTILISATION
WO2014197460A1 (fr) * 2013-06-04 2014-12-11 The Trustees Of The University Of Pennsylvania Procédés de diagnostic et de traitement de la bicuspidie valvulaire aortique et/ou d'aortopathies
CN113150145B (zh) 2013-08-30 2025-02-14 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
EP3077823B1 (fr) 2013-12-05 2019-09-04 The Broad Institute, Inc. Compositions et méthodes pour identifier et traiter la cachexie ou la pré-cachexie
EP3207062A1 (fr) * 2014-10-16 2017-08-23 The Broad Institute Inc. Compositions et méthodes pour identifier et traiter la cachexie ou la pré-cachexie
JP6679096B2 (ja) * 2014-10-21 2020-04-15 学校法人 久留米大学 Ｒａｇｅアプタマーおよびその用途
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
EP3294335B1 (fr) * 2015-05-12 2023-07-05 Syntimmune Inc. Anticorps anti-fcrn à maturation d'affinité humanisés
EP4679095A3 (fr) 2015-05-18 2026-05-06 Agensys, Inc. Anticorps se liant à des protéines axl
WO2016187354A1 (fr) 2015-05-18 2016-11-24 Agensys, Inc. Anticorps se liant à des protéines axl
EP3822291A1 (fr) 2015-06-10 2021-05-19 The Broad Institute Inc. Anticorps, composés et écrans permettant l'identification et le traitement la cachexie ou pré-cachexie
WO2016201319A1 (fr) * 2015-06-10 2016-12-15 The Broad Institute Inc. Anticorps, composés et écrans d'identification et de traitement de cachexie ou pré-cachexie
JP6578595B2 (ja) * 2015-08-28 2019-09-25 国立研究開発法人科学技術振興機構 抗アセチル化ヒストンｈ４抗体
WO2017043466A1 (fr) * 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anticorps anti-epha4
CN116440279B (zh) 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
WO2017106196A1 (fr) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions et procédés de traitement des dysfonctionnements cardiaques
CN113512111B (zh) * 2017-03-10 2023-08-15 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
JP7262440B2 (ja) * 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ４７抗体及びその使用
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
EP3990494A1 (fr) * 2019-06-26 2022-05-04 GlaxoSmithKline Intellectual Property Development Limited Protéines de liaison à l'il1rap
CA3156803A1 (fr) * 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions et methodes comprenant des anticorps anti-nrp2
WO2022019924A1 (fr) * 2020-07-23 2022-01-27 Church William R Anticorps spécifique de staphylococcus aureus, méthode thérapeutique et méthode de détection de celui-ci
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
CN118574852A (zh) * 2021-11-18 2024-08-30 萨尔瓦瑞克斯有限责任公司 晚期糖基化终末产物受体（rage）的抗体及其用途
CN116554311B (zh) * 2023-05-04 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗CD2v-N的特异性抗体及其应用
KR20250001879A (ko) 2023-06-28 2025-01-07 주식회사 세바바이오텍 완도호랑가시나무와 노루궁뎅이버섯 추출물을 유효성분으로 포함하는 최종당화산물 억제용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1167379A3 (fr) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Oligonucléotides immunomodulateurs
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
RU2413520C2 (ru) 2000-06-08 2011-03-10 Интерселл Аг Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2418854A1 (fr) 2000-08-17 2002-02-21 Jorg Fritz Vaccin comprenant au moins un antigene et un peptide antimicrobien a base de cathelicidine ou un derive de ce peptide
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
WO2002094845A2 (fr) 2001-05-21 2002-11-28 Intercell Ag Procede de stabilisation des acides nucleiques
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CA2645125A1 (fr) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Procedes de diagnostic du cancer du pancreas utilisant la proteine reg4
CN101448857A (zh) * 2006-03-21 2009-06-03 惠氏公司 预防和治疗淀粉样蛋白生成疾病的方法
WO2007109749A2 (fr) * 2006-03-21 2007-09-27 Wyeth Procedes de prevention et de traitement des maladies amyloidogenes
JP2009541275A (ja) * 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
WO2008137552A2 (fr) * 2007-05-02 2008-11-13 Medimmune, Llc Anticorps anti-rage et procédés d'utilisation de ceux-ci
EP2116556B1 (fr) * 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Anticorps contre récepteur de produit terminal de glycosylation (RAGE) et utilisations associées

Also Published As

Publication number Publication date
TN2012000138A1 (en) 2013-09-19
ECSP12011787A (es) 2012-10-30
RU2012118598A (ru) 2013-11-20
ZA201202099B (en) 2012-11-28
AU2010305374A1 (en) 2012-05-03
MX2012004090A (es) 2012-04-20
CN102686611A (zh) 2012-09-19
EP2486058A1 (fr) 2012-08-15
CA2777237A1 (fr) 2011-04-14
JP2013507115A (ja) 2013-03-04
US20120282637A1 (en) 2012-11-08
PE20121689A1 (es) 2012-12-14
BR112012007821A2 (pt) 2017-05-30
CL2012000886A1 (es) 2012-12-14
MA33661B1 (fr) 2012-10-01
CR20120139A (es) 2012-07-13
PH12012500564A1 (en) 2012-10-22
KR20120089863A (ko) 2012-08-14
WO2011042548A1 (fr) 2011-04-14
RU2558301C2 (ru) 2015-07-27

Similar Documents

Publication Publication Date Title
IL218968A0 (en) Polypeptides for binding the " receptor for advanced glycation endproducts" as well as compositions and methods involving the same
IL254498A0 (en) Methods for preparing purified polypeptide preparations
IL252561B (en) Antibodies against Siglac-15 polynucleotides encoding them, preparations containing them and their uses
ZA201006944B (en) Compositions and methods for preparing and using same
EP2185201A4 (fr) Compositions et procédés permettant la cristallisation d'anticorps
IL229564A0 (en) Substances that bind receptors of the cell nucleus, their pharmaceutical components and their uses
EP2193145A4 (fr) Compositions et procédés comprenant des protéines de liaison pour adalimumab
IL212589A0 (en) Binding proteins inhibiting the vegf-a receptor interaction
EP2214623A4 (fr) Composition cosmétique pulvérulente
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
EP2069401A4 (fr) Protéines de liaison à épitope multispécifiques et leurs utilisations
SI2137210T1 (sl) Nov postopek in sestavki
PT2155818T (pt) Composições de juntas
PT2572726T (pt) Composições compreendendo antigénios pneumocócicos
GB0722484D0 (en) Solid compositions
EP2219458A4 (fr) Compositions et procédés de production d'anticorps
EP2282735A4 (fr) Composés, compositions et procédés pour préparer ceux-ci
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
GB0706077D0 (en) Methods, Compositions and uses thereof
ZA200904611B (en) Epilatory compositions
EP2150818A4 (fr) Composition et procédés pour combiner des anticorps de signalement
IL215887A (en) Capsule liver cell preparations, methods of preparation and use thereof
PL386709A1 (pl) Kompozycja oczyszczająca
HK1167667A (en) Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
GB0712194D0 (en) Herbal composition